RO 7446603
Alternative Names: RO-7446603Latest Information Update: 05 Jul 2022
At a glance
- Originator Roche
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetic macular oedema
Most Recent Events
- 22 Jun 2022 Phase-I clinical trials in Diabetic macular oedema (Combination therapy) in USA (Intravitreous) (ISRCTN14152148)
- 22 Jun 2022 Phase-I clinical trials in Diabetic macular oedema in USA (Intravitreous) (ISRCTN14152148)